Literature DB >> 25103225

Oral administration of bisphenol A induces high blood pressure through angiotensin II/CaMKII-dependent uncoupling of eNOS.

Marta Saura1, Susana Marquez1, Paula Reventun1, Nuria Olea-Herrero2, María Isabel Arenas3, Rafael Moreno-Gómez-Toledano2, Mónica Gómez-Parrizas4, Carmen Muñóz-Moreno2, Marta González-Santander5, Carlos Zaragoza6, Ricardo J Bosch2.   

Abstract

Bisphenol A (BPA) is found in human urine and fat tissue. Higher urinary BPA concentrations are associated with arterial hypertension. To shed light on the underlying mechanism, we orally administered BPA (4 nM to 400 μM in drinking water) to 8-wk-old CD11 mice over 30 d. Mice developed dosage-dependent high blood pressure (systolic 130 ± 12 vs. 170 ± 12 mmHg; EC50 0.4 μM), impairment of acetylcholine (AcH)-induced carotid relaxation (0.66 ± 0.08 vs. 0.44 ± 0.1 mm), a 1.7-fold increase in arterial angiotensin II (AngII), an 8.7-fold increase in eNOS mRNA and protein, and significant eNOS-dependent superoxide and peroxynitrite accumulation. AngII inhibition with 0.5 mg/ml losartan reduced oxidative stress and normalized blood pressure and endothelium-dependent relaxation, which suggests that AngII uncouples eNOS and contributes to the BPA-induced endothelial dysfunction by promoting oxidative and nitrosative stress. Microarray analysis of mouse aortic endothelial cells revealed a 2.5-fold increase in expression of calcium/calmodulin-dependent protein kinase II-α (CaMKII-α) in response to 10 nM BPA, with increased expression of phosphorylated-CaMKII-α in carotid rings of BPA-exposed mice, whereas CaMKII-α inhibition with 100 nM autocamptide-2-related inhibitor peptide (AIP) reduced BPA-mediated increase of superoxide. Administration of CaMKII-α inhibitor KN 93 reduced BPA-induced blood pressure and carotid blood velocity in mice, and reverted BPA-mediated carotid constriction in response to treatment with AcH. Given that CaMKII-α inhibition prevents BPA-mediated high blood pressure, our data suggest that BPA regulates blood pressure by inducing AngII/CaMKII-α uncoupling of eNOS. © FASEB.

Entities:  

Keywords:  AngII; BPA; endothelial dysfunction; hypertension; superoxide

Mesh:

Substances:

Year:  2014        PMID: 25103225     DOI: 10.1096/fj.14-252460

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

1.  Ca2+/calmodulin-dependent protein kinase II-γ (CaMKIIγ) negatively regulates vascular smooth muscle cell proliferation and vascular remodeling.

Authors:  Fatima Z Saddouk; Li-Yan Sun; Yong Feng Liu; Miao Jiang; Diane V Singer; Johannes Backs; Dee Van Riper; Roman Ginnan; John J Schwarz; Harold A Singer
Journal:  FASEB J       Date:  2015-11-13       Impact factor: 5.191

2.  The Choice of Hemodialysis Membrane Affects Bisphenol A Levels in Blood.

Authors:  Enrique Bosch-Panadero; Sebastian Mas; Didier Sanchez-Ospina; Vanesa Camarero; Maria V Pérez-Gómez; Isabel Saez-Calero; Pedro Abaigar; Alberto Ortiz; Jesus Egido; Emilio González-Parra
Journal:  J Am Soc Nephrol       Date:  2015-10-02       Impact factor: 10.121

Review 3.  Lifestyle interventions for the prevention and treatment of hypertension.

Authors:  Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia
Journal:  Nat Rev Cardiol       Date:  2020-10-09       Impact factor: 32.419

Review 4.  EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.

Authors:  A C Gore; V A Chappell; S E Fenton; J A Flaws; A Nadal; G S Prins; J Toppari; R T Zoeller
Journal:  Endocr Rev       Date:  2015-11-06       Impact factor: 19.871

Review 5.  Ecology of the cardiovascular system: Part II - A focus on non-air related pollutants.

Authors:  J F Argacha; T Mizukami; T Bourdrel; M-A Bind
Journal:  Trends Cardiovasc Med       Date:  2018-09-08       Impact factor: 6.677

6.  Clofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPARα) Agonist, and Its Molecular Mechanisms of Action against Sodium Fluoride-Induced Toxicity.

Authors:  Ademola Adetokunbo Oyagbemi; Olumuyiwa Abiola Adejumobi; Theophilus Aghogho Jarikre; Olumide Samuel Ajani; Ebunoluwa Racheal Asenuga; Idayat Titilayo Gbadamosi; Aduragbenro Deborah A Adedapo; Abimbola Obemisola Aro; Blessing Seun Ogunpolu; Fasilat Oluwakemi Hassan; Olufunke Olubunmi Falayi; Iyanuoluwa Omolola Ogunmiluyi; Temidayo Olutayo Omobowale; Oluwatosin Adetola Arojojoye; Olufunke Eunice Ola-Davies; Adebowale Benard Saba; Adeolu Alex Adedapo; Benjamin Obukowho Emikpe; Matthew Olugbenga Oyeyemi; Sanah Malomile Nkadimeng; Lyndy Joy McGaw; Prudence Ngalula Kayoka-Kabongo; Oluwafemi Omoniyi Oguntibeju; Momoh Audu Yakubu
Journal:  Biol Trace Elem Res       Date:  2021-04-24       Impact factor: 3.738

7.  Comparative analysis of mite genomes reveals positive selection for diet adaptation.

Authors:  Qiong Liu; Yuhua Deng; An Song; Yifan Xiang; Lai Wei
Journal:  Commun Biol       Date:  2021-06-03

8.  Bisphenol A Modulates Autophagy and Exacerbates Chronic Kidney Damage in Mice.

Authors:  Alberto Ruiz Priego; Emilio González Parra; Sebastián Mas; José Luis Morgado-Pascual; Marta Ruiz-Ortega; Sandra Rayego-Mateos
Journal:  Int J Mol Sci       Date:  2021-07-03       Impact factor: 5.923

9.  Calcium/calmodulin-dependent kinase II inhibition in smooth muscle reduces angiotensin II-induced hypertension by controlling aortic remodeling and baroreceptor function.

Authors:  Anand M Prasad; Donald A Morgan; Daniel W Nuno; Pimonrat Ketsawatsomkron; Thomas B Bair; Ashlee N Venema; Megan E Dibbern; William J Kutschke; Robert M Weiss; Kathryn G Lamping; Mark W Chapleau; Curt D Sigmund; Kamal Rahmouni; Isabella M Grumbach
Journal:  J Am Heart Assoc       Date:  2015-06-15       Impact factor: 5.501

10.  Bisphenol A exposure alters placentation and causes preeclampsia-like features in pregnant mice involved in reprogramming of DNA methylation of WNT2.

Authors:  Yunzhen Ye; Yao Tang; Yu Xiong; Liping Feng; Xiaotian Li
Journal:  FASEB J       Date:  2018-10-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.